Skip to main content
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. — Investor Relations & Filings

Ticker · NAMS ISIN · NL00150012K9 LEI · 984500B6549TF6E14D36 US Professional, scientific and technical activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2025-06-11 Investor Presentation
Country NL Netherlands
Listing US NAMS

About NewAmsterdam Pharma Co N.V.

https://ir.newamsterdampharma.com/

NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases where currently approved treatments have not been sufficiently successful or well-tolerated. The company's lead product candidate is obicetrapib, an oral, low-dose, once-daily CETP inhibitor. It is being investigated as a therapy to lower low-density lipoprotein cholesterol (LDL-C) as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. The company aims to address the unmet need for a potent, cost-effective, and convenient LDL-lowering treatment. In addition to its dyslipidemia program, the company also explores treatments for other metabolic disorders.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions a Research & Development Day event and includes a presentation as Exhibit 99.1. The document states that the presentation is "furnished" and not "filed," indicating it is an investor presentation rather than a formal financial report. The length is 4228 characters, which is relatively short and consistent with an event announcement and presentation attachment. There is no detailed financial data or quarterly/yearly financial statements present. Therefore, the document fits best as an Investor Presentation (IP).
2025-06-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or disclosures by a company. The text includes a press release about positive topline data from a Phase 3 clinical trial, furnished as an exhibit. There are no detailed financial statements or comprehensive financial analysis present. The document is primarily an announcement of clinical trial results and related forward-looking statements, not a full financial report or earnings release. It is not a certification or officer attestation. Given the nature of the Form 8-K and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, reporting the results of the 2025 Annual General Meeting (AGM) of NewAmsterdam Pharma Company N.V. It details the voting outcomes on various proposals including approval of annual accounts, discharge of directors, appointment of auditors, director elections, share acquisition authorizations, and advisory votes on executive compensation (Say-on-Pay). The document is focused on the submission of matters to a vote of security holders and the official voting results. It does not contain the full annual report, financial statements, or detailed management discussion, but rather the official voting results from the AGM. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)". The document length (6960 characters) and content confirm it is not a full annual report or other report type but a voting results announcement.
2025-06-06 English
4
Director's Dealing
2025-06-03 English
4
Director's Dealing
2025-06-03 English
3
Director's Dealing
2025-06-03 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.